X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
INDRAPRASTHA MEDICAL Fact Sheet, INDRAPRASTHA MEDICAL Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDRAPRASTHA MEDICAL Fact Sheet   (IRMED)

Here is the latest financial fact sheet of INDRAPRASTHA MEDICAL. For more details, see the INDRAPRASTHA MEDICAL quarterly results and INDRAPRASTHA MEDICAL share price and chart. For a sector overview, read our pharmaceuticals sector report.

INDRAPRASTHA MEDICAL Price History

Price Rs 53.1
Mkt Cap Rs m 4,868
Vol '000 4.4
P/E X 17.5
P/CF X 7.7
EPS (TTM) Rs 3.0
% ch % -1.1
No. of shares m 91.67
% ch week % -1.5
% ch 1-mth % -3.3
% ch 12-mth % 2.0
52 week H/L Rs 64.3/45.0
(As on Jun 23, 2017 10:44:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

INDRAPRASTHA MEDICAL Financials

No. of Mths
Year Ending
12
Mar-10
12
Mar-11
12
Mar-12
12
Mar-13
12
Mar-14
5-Yr Chart
Click to enlarge
INDRAPRASTHA MEDICAL EQUITY SHARE DATA
High Rs5453444241 
Low Rs2830313229 
Sales per share (Unadj.) Rs46.347.554.964.572.0 
Earnings per share (Unadj.) Rs3.43.42.93.13.9 
Diluted earnings per shareRs3.43.42.93.13.9 
Cash flow per share (Unadj.) Rs5.55.75.36.06.9 
Dividends per share (Unadj.) Rs1.601.601.601.601.80 
Adj. dividends per shareRs1.601.601.601.601.80 
Dividend yield (eoy) %3.93.94.34.35.1 
Book value per share (Unadj.) Rs14.816.317.418.720.4 
Adj. book value per shareRs14.816.317.418.720.4 
Shares outstanding (eoy) m91.6791.6791.6791.6791.67 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.90.90.70.60.5 
Avg P/E ratio x12.112.412.711.99.1 
P/CF ratio (eoy) x7.57.37.06.35.1 
Price / Book Value ratio x2.82.52.22.01.7 
Dividend payout %47.247.754.351.046.6 
Avg Mkt Cap Rs m3,7583,8043,4383,4283,222 
No. of employees `0002.93.02.93.23.1 
Total wages/salary Rs m8249851,1781,2661,418 
Avg. sales/employee Rs Th1,444.11,430.61,739.21,871.02,125.7 
Avg. wages/employee Rs Th280.5323.7407.3400.6456.6 
Avg. net profit/employee Rs Th105.7101.093.491.0114.1 
INDRAPRASTHA MEDICAL INCOME DATA
Net Sales Rs m4,2444,3555,0305,9126,600 
Other income Rs m121269197169186 
Total revenues Rs m4,3654,6245,2266,0826,786 
Gross profit Rs m576434481631733 
Depreciation Rs m193216218259281 
Interest Rs m3944598696 
Profit before tax Rs m466443400455542 
Minority Interest Rs m00000 
Prior Period Items Rs m09000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m155145130167187 
Profit after tax Rs m311307270288354 
Gross profit margin %13.610.09.610.711.1 
Effective tax rate %33.332.832.536.834.6 
Net profit margin %7.37.15.44.95.4 
INDRAPRASTHA MEDICAL BALANCE SHEET DATA
Current assets Rs m9079501,1941,3201,473 
Current liabilities Rs m1,3191,2821,7631,9621,920 
Net working cap to sales %-9.7-7.6-11.3-10.9-6.8 
Current ratio x0.70.70.70.70.8 
Inventory Days Days88777 
Debtors Days Days2427243236 
Net fixed assets Rs m2,0952,5982,7583,0032,947 
Share capital Rs m917917917917917 
"Free" reserves Rs m440577676793955 
Net worth Rs m1,3571,4931,5931,7101,871 
Long term debt Rs m44427279297258 
Total assets Rs m3,0023,5814,0204,3814,488 
Interest coverage x13.111.27.86.36.7 
Debt to equity ratio x00.30.20.20.1 
Sales to assets ratio x1.41.21.31.31.5 
Return on assets %11.69.88.28.510.0 
Return on equity %22.920.617.016.818.9 
Return on capital %36.025.824.527.029.9 
Exports to sales %00000 
Imports to sales %2.97.12.84.01.8 
Exports (fob) Rs m00000 
Imports (cif) Rs m122308140238116 
Fx inflow Rs m4015477367031,116 
Fx outflow Rs m141344197319218 
Net fx Rs m260203539384898 
INDRAPRASTHA MEDICAL CASH FLOW
From Operations Rs m 730 334 555 669 581 
From Investments Rs m -361 -573 -280 -540 -218 
From Financial Activity Rs m -357 219 -268 -126 -361 
Net Cashflow Rs m 13 -20 7 3 2 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 49.4%
Foreign collaborators 1.6%
Indian inst/Mut Fund 1.3%
FIIs 0.5%
ADR/GDR 0.0%
Free float 47.2%
Shareholders 38,169
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Sarita Vihar, Delhi - Mathura Road, New Delhi - 110 076
E-MAIL asinghal@apollohospitals.com WEB www.apollohospdelhi.com
TELEPHONE (011) 2692 5858 FAX (011) 2682 5601
SECTOR HEALTH SERVICES GROUP MISCELLANEOUS
TR AGENT Link Intime India, 44, 2nd Flr., Naraina Indl. Area, Phase I, New Delhi-28
AUDITOR S. C. Vasudeva & Co.
CHM: S. K. Srivastava COMP SEC: A. K. Singhal YEAR OF INC: 1900 BSE CODE: 532150 FV (Rs): 10 DIV YIELD (%): 3.4

More Health Services Company Fact Sheets:   CADILA HEALTHCARE  AMAR REMEDIES  TTK HEALTHCARE  ELDER PHARMA  ASTRAZENECA PHARMA  

Compare INDRAPRASTHA MEDICAL With:   CADILA HEALTHCARE  AMAR REMEDIES  TTK HEALTHCARE  ELDER PHARMA  ASTRAZENECA PHARMA  

Compare INDRAPRASTHA MEDICAL With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Off to a Cautious Start; Realty & Power Stocks Gain(09:30 am)

Most of the Asian equity markets are lower today after the sell-off in mainland China markets in the previous trading session. The Shanghai Composite is off 0.13% while the Hang Seng is down 0.21%.

Views on news

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

More Views on News

Most Popular

Digital Transactions were Growing Faster Before Demonetisation(Vivek Kaul's Diary)

Jun 12, 2017

Which brings us back to the basic question, why was demonetisation carried out?

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Should You Trade In Mutual Funds As You Do In Stocks?(Outside View)

Jun 10, 2017

Trading is not synonymous with mutual funds, PersonalFN explains.

Which Way Will Inflation Go?(Chart Of The Day)

Jun 10, 2017

RBI and government at loggerheads over interest rates.

More

TRACK INDRAPRASTHA MEDICAL

  • Track your investment in INDRAPRASTHA MEDICAL with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDRAPRASTHA MEDICAL

INDRAPRASTHA MEDICAL - FORTIS HEALTHCARE COMPARISON

COMPARE INDRAPRASTHA MEDICAL WITH

MARKET STATS